摘要
钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型口服降糖药,对2型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局。虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍排除了eGFR<20 mL/(min·1.73 m 2)的患者,SGLT2i的心肾保护作用能否延续至维持性透析期是临床关注的重点。此外,SGLT2i的抗炎和抗纤维化作用可能对腹膜透析(PD)患者维持腹膜功能有益。因此,SGLT2i在PD患者中的应用值得进一步探索。
Sodium-glucose co-transporter 2 inhibitors(SGLT2i),a novel type of oral antihyperglycaemic drugs,have demonstrated favorable cardiorenal protective effects in patients with type 2 diabetes or non-diabetic individuals.They can also improve cardiorenal outcomes in patients with chronic kidney disease.Although clinical trials have expanded the inclusion criteria for estimated glomerular filtration rate(eGFR)to lower levels,patients with eGFR<20 ml/min/1.73m^2 are still excluded.Whether the continuation of cardiorenal protective effects of SGLT2i during the maintenance dialysis phase is an area of clinical focus.Additionally,the anti-inflammatory and anti-fibrotic properties of SGLT2i may benefit the preservation of peritoneal function in patients undergoing peritoneal dialysis(PD).Therefore,further exploration of the application of SGLT2i in PD patients is warranted.
作者
余乐
成水芹(综述)
俞雨生(审校)
YU Le;CHENG Shuiqin;YU Yusheng(National Clinical Research Center for Kidney Diseases,Jinling Hospital,Nanjing 210016,China)
出处
《肾脏病与透析肾移植杂志》
CAS
CSCD
2024年第4期372-376,共5页
Chinese Journal of Nephrology,Dialysis & Transplantation
基金
国家自然科学基金面上项目(82370733)。
关键词
钠-葡萄糖协同转运蛋白2抑制剂
腹膜透析
心肾保护
残余肾功能
腹膜
sodium-glucose co-transporter 2 inhibitors
peritoneal dialysis
cardiorenal protection
residual kidney function
peritoneal membrane
